FLS care effective for patients with fragility fractures

FLS care effective for patients with fragility fractures

NTHU research team develops new treatment for cancer A total of 23 subsequent fractures occurred in 21 patients over nearly 900 person-years, with a rate of 2.6 percent per 100 person-years. That rate was lower than those suggested by past studies of patients with fragility fractures in the general population, which have ranged from 4 to 10 per 100 person-years. Laboratory tests showed significant improvements bone metabolism during FLS care, including a slower rate of bone turnover. Standard measures of functional capacity and disability improved, while pain scores decreased. Despite its growing popularity, there are still limited data on the effectiveness of the FLS approach. While previous "real world" studies of FLS care have reported high rates of testing and treatment, this new study is one of the first to include the results of systematic follow-up, including subsequent fracture rates. The results suggest real benefits of FLS care for patients with fragility fractures, including testing, treatment, and follow-up participation rates over 80 percent. This study also suggests that FLS care is associated with a low rate of subsequent fractures, with reduced bone turnover and improved functional capacity. Although this new analysis doesn't include a comparison group of patients not receiving FLS care, historical data from previous studies support their findings. A randomized controlled trial with a larger sample and a longer follow-up period would better quantify the yield of improvement over the usual care." Dr. Fernandes and colleagues Wolters Kluwer Journal reference: Senay, A., et al. (2020) Performance of a Fracture Liaison Service in an Orthopaedic Setting, A Report of Key Indicators and Improvement of Longitudinal Outcomes. The Journal of Bone and Joint Surgery . doi.org/10.2106/JBJS.19.00185 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More